Wall Street analysts expect Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to announce sales of $5.00 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Collegium Pharmaceutical’s earnings. The lowest sales estimate is $4.74 million and the highest is $5.25 million. Collegium Pharmaceutical posted sales of $410,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 1,119.5%. The business is scheduled to report its next earnings report after the market closes on Wednesday, November 8th.
According to Zacks, analysts expect that Collegium Pharmaceutical will report full year sales of $5.00 million for the current financial year, with estimates ranging from $16.76 million to $21.00 million. For the next year, analysts forecast that the company will report sales of $58.07 million per share, with estimates ranging from $42.10 million to $68.26 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Collegium Pharmaceutical.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $0.09. Collegium Pharmaceutical had a negative return on equity of 93.73% and a negative net margin of 1,319.39%. The firm had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $4.07 million.
A number of equities research analysts have commented on the company. Zacks Investment Research cut Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Piper Jaffray Companies set a $14.00 price objective on Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Tuesday, July 25th. Needham & Company LLC reissued a “buy” rating and issued a $25.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, October 6th. Jefferies Group LLC reissued a “buy” rating and issued a $15.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, October 6th. Finally, BidaskClub lowered Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $20.00.
COPYRIGHT VIOLATION WARNING: “$5.00 Million in Sales Expected for Collegium Pharmaceutical, Inc. (COLL) This Quarter” was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.com-unik.info/2017/11/06/5-00-million-in-sales-expected-for-collegium-pharmaceutical-inc-coll-this-quarter.html.
Shares of Collegium Pharmaceutical (COLL) opened at $9.82 on Monday. Collegium Pharmaceutical has a one year low of $7.37 and a one year high of $18.02.
Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Collegium Pharmaceutical by 7.8% in the first quarter. Vanguard Group Inc. now owns 806,539 shares of the specialty pharmaceutical company’s stock valued at $8,113,000 after purchasing an additional 58,398 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Collegium Pharmaceutical by 60.7% in the second quarter. Bank of New York Mellon Corp now owns 104,961 shares of the specialty pharmaceutical company’s stock valued at $1,313,000 after purchasing an additional 39,656 shares in the last quarter. Pier Capital LLC lifted its holdings in shares of Collegium Pharmaceutical by 8.1% in the second quarter. Pier Capital LLC now owns 395,658 shares of the specialty pharmaceutical company’s stock valued at $4,950,000 after purchasing an additional 29,594 shares in the last quarter. Morgan Stanley lifted its holdings in shares of Collegium Pharmaceutical by 684.8% in the first quarter. Morgan Stanley now owns 885,268 shares of the specialty pharmaceutical company’s stock valued at $8,906,000 after purchasing an additional 772,464 shares in the last quarter. Finally, Macquarie Group Ltd. lifted its holdings in shares of Collegium Pharmaceutical by 37.1% in the second quarter. Macquarie Group Ltd. now owns 1,118,691 shares of the specialty pharmaceutical company’s stock valued at $13,995,000 after purchasing an additional 302,892 shares in the last quarter. Institutional investors own 83.06% of the company’s stock.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Collegium Pharmaceutical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Collegium Pharmaceutical Inc. and related companies.